Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson with an Outperform rating and $190 price target ...

J&J wants to appoint lawyer Randi Ellis, who helped it prepare for its third talc-related chapter 11 filing, but the U.S.

Johnson & Johnson announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% ...

Johnson & Johnson’s rebate model aims to address misuse of 340B Program. HRSA’s threats of penalties led J&J to halt the plan ...

In trading on Monday, shares of Johnson & Johnson entered into oversold territory, hitting an RSI reading of 29.5 ...

Johnson & Johnson MedTech announced today that the FDA granted its Ottava surgical robot investigational device exemption ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...